Precision BioSciences Inc. Common Stock (DTIL)

FairStock Score: 62/100 — STEADY

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.31, providing financial flexibility
• Superior net profit margin of 58.8% indicating pricing power and operational efficiency
• Revenue growth of 5261.1% demonstrates strong top-line momentum

Concerns

• Altman Z-Score of -1.6 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Precision BioSciences Inc. Common Stock is a micro-cap healthcare company valued at $194 million. The business generates $34 million in annual revenue with a 58.8% net margin. From a quality standpoint, Precision shows distressed Altman Z-Score of -1.6 warrants caution and negative ROE indicating losses. Growth dynamics show revenue growing at 5261.1% and profit growth of 213.5%. Our composite FairStock Score of 62/100 reflects above-average fundamentals overall. Investors should weigh the business quality against the current price and their own margin of safety requirements.

Bull Case

Precision's 5261% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Macro headwinds or sector-specific disruption could pressure margins, particularly if competitive intensity increases in the healthcare space. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer